On Wednesday, Axsome Therapeutics reached an important technical milestone, with its Relative Strength (RS) Rating jumping into the 80-plus percentile with an improvement to 85, a rise from 70 the day before. Axsome Therapeutics is now considered extended and out of buy range. Market volatility is key, however.
Read More